Scynexis (SCYX) Common Equity (2013 - 2026)
Scynexis' (SCYX) quarterly Common Equity came in at $66.9 million in Q2 2026, up 50.52% on a YoY basis from $44.5 million in Q2 2025, and up 62.03% quarter-over-quarter from $41.3 million in Q1 2026.
Analysis
Scynexis (SCYX) Common Equity (2013 - 2026) Analysis & Trends
Scynexis (SCYX) has reported Common Equity for 14 consecutive years, with $66.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Common Equity rose 50.52% year-over-year to $66.9 million; the trailing twelve-month figure through Jun 2026 stood at $66.9 million (up 50.52% YoY), and the FY2025 full-year result was $49.4 million, down 10.35% from the prior year.
- Common Equity grew to $66.9 million in Q2 2026 per SCYX's latest filing, from $41.3 million in the prior quarter.
- Across five years, Common Equity topped out at $150.0 million in Q3 2022 and bottomed at -$29.9 million in Q1 2023.
- Historically, Common Equity has averaged $55.7 million across 5 years, with a median of $52.8 million in 2024.
- The widest YoY moves for Common Equity: up 2156.79% in 2023, down 176.85% in 2023.
- Over 5 years, Common Equity stood at $3.2 million in 2022, then jumped by 2156.79% to $73.0 million in 2023, then fell by 24.51% to $55.1 million in 2024, then declined by 10.35% to $49.4 million in 2025, then jumped by 35.55% to $66.9 million in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $66.9 million, $41.3 million, and $49.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 11.69 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 11.83 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 20.25 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 31.71 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 8.42 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 6.76 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.35 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 18.85 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 4.92 Bn |
| 10 | Scynexis | 58.41 Mn | -56.29 Mn | - | 66.93 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 66.93 Mn |
| Mar 31, 2026 | 41.31 Mn |
| Dec 31, 2025 | 49.38 Mn |
| Sep 30, 2025 | 36.43 Mn |
| Jun 30, 2025 | 44.47 Mn |
| Mar 31, 2025 | 50.53 Mn |
| Dec 31, 2024 | 55.08 Mn |
| Sep 30, 2024 | 58.53 Mn |
| Jun 30, 2024 | 60.41 Mn |
| Mar 31, 2024 | 74.11 Mn |
| Dec 31, 2023 | 72.96 Mn |
| Sep 30, 2023 | 91.99 Mn |
| Jun 30, 2023 | 93.08 Mn |
| Mar 31, 2023 | -29.91 Mn |
| Dec 31, 2022 | 3.23 Mn |
| Sep 30, 2022 | 150.00 Mn |
| Jun 30, 2022 | 45.48 Mn |
| Mar 31, 2022 | 38.93 Mn |
| Dec 31, 2021 | 41.26 Mn |
| Sep 30, 2021 | 37.61 Mn |